The cost–effectiveness of infliximab in Crohn’s disease

References

• Aufses AH. The history of Crohn’s disease. Surg Clin North Am 2001;81(1):1-11, vii
   PubMedGoogle Scholar
• Kirsner JB. Historical aspects of inflammatory bowel disease. J Clin Gastroenterol 1988;10(3):286-97
   PubMedGoogle Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54; e42; quiz e30
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 1992;27(7):609-14
   PubMed Web of Science ®Google Scholar
• Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17
   PubMed Web of Science ®Google Scholar
• Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14(12):1553-9
   PubMedGoogle Scholar
• Yapp TR, Stenson R, Thomas GA, et al. Crohn’s disease incidence in Cardiff from 1930: an update for 1991-1995. Eur J Gastroenterol Hepatol 2000;12(8):907-11
   PubMed Web of Science ®Google Scholar
• Ehlin AG, Montgomery SM, Ekbom A, et al. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut 2003;52(8):1117-21
   PubMedGoogle Scholar
• Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol 2003;15(12):1275-80
   PubMedGoogle Scholar
• Carter MJ, Lobo AJ, Travis SP; IBD Section BiSoG. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5)):V1-16
   PubMedGoogle Scholar
• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1)):S3-9
   Google Scholar
• Heresbach D, Alexandre JL, Bretagne JF, et al. Crohn’s disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol 2004;16(7):657-64
   PubMedGoogle Scholar
• Bayless TM, Tokayer AZ, Polito JM, et al. Crohn’s disease: concordance for site and clinical type in affected family members – potential hereditary influences. Gastroenterology 1996;111(3):573-9
   PubMed Web of Science ®Google Scholar
• Freeman HJ. Familial Crohn’s disease in single or multiple first-degree relatives. J Clin Gastroenterol 2002;35(1):9-13
   PubMedGoogle Scholar
• Higuchi LM, Khalili H, Chan AT, et al. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol 2012;107(9):1399-406
   PubMedGoogle Scholar
• Lawrance IC, Murray K, Batman B, et al. Crohn’s disease and smoking: is it ever too late to quit? J Crohns Colitis 2013;7(12):e665-71
   Google Scholar
• Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn’s disease and ulcerative colitis. Am J Gastroenterol 2011;106(12):2133-42
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012;156(5):350-9
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect Dis 2007;7(9):607-13
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005;11(2):154-63
   PubMed Web of Science ®Google Scholar
• Amre DK, D’Souza S, Morgan K, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn’s disease in children. Am J Gastroenterol 2007;102(9):2016-25
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn’s disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42(5):602-10
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ; Gastroenterology PPCoACo. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104(2):465-83; quiz 464, 484
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Nion-Larmurier I, et al. Factors affecting outcomes in Crohn’s disease over 15 years. Gut 2012;61(8):1140-5
   PubMed Web of Science ®Google Scholar
• Selinger CP, Andrews JM, Titman A, et al. Long-term follow up reveals low incidence of colorectal cancer, but frequent need for resection, among australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12(4):644-50
   PubMedGoogle Scholar
• Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59(9):1200-6
   PubMed Web of Science ®Google Scholar
• Selinger CP, Leong RW. Mortality from inflammatory bowel diseases. Inflamm Bowel Dis 2012;18(8):1566-72
   PubMedGoogle Scholar
• Selinger CP, Andrews J, Dent OF, et al. Cause-specific mortality and 30-year relative survival of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2013;19(9):1880-8
   PubMed Web of Science ®Google Scholar
• Hovde O, Kempski-Monstad I, Småstuen MC, et al. Mortality and causes of death in Crohn’s disease: results from 20 years of follow-up in the IBSEN study. Gut 2014;63(5):771-5
   PubMed Web of Science ®Google Scholar
• Lönnfors S, Vermeire S, Greco M, et al. IBD and health-related quality of life - Discovering the true impact. J Crohns Colitis 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8(2):93-106
   PubMed Web of Science ®Google Scholar
• Cohen BL, Zoëga H, Shah SA, et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther 2014;39(8):811-22
   PubMed Web of Science ®Google Scholar
• The IBD Standards Group. Quality Care Service standards for people who have Inflammatory Bowel Disease (IBD). 2009
   Google Scholar
• Crohns & Colitis Australia. Deloitte Access Economics Report on IBD in Australia, June 2007. Available from: www.crohnsandcolitis.com.au/content/Deloitte_ Access_Economics_Report_on_IBD_in_Australia_Jun_2007.pdf
   Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4(1):28-62
   PubMed Web of Science ®Google Scholar
• Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther 2010;32(11-12):1357-63
   PubMedGoogle Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999;117(4):761-9
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340(18):1398-405
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350(9):876-85
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2(10):912-20
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132(3):863-73; quiz 1165-1166
   PubMed Web of Science ®Google Scholar
• Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 2003;98(4):833-8
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009;136(2):441-50; e441; quiz 716
   PubMed Web of Science ®Google Scholar
• Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol 2014. [ Epub ahead of print]
   Google Scholar
• Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess 2011;15(6):1-244
   PubMed Web of Science ®Google Scholar
• Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 2003;7(3):1-67
   PubMedGoogle Scholar
• Jaisson-Hot I, Flourié B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004;20(3):274-9
   PubMed Web of Science ®Google Scholar
• Marshall JK, Blackhouse G, Goeree R, et al. Technology overview - clinical and economic assessment: infliximab for the treatment of Crohn’s disease. Canadian Coordinating Office for Health Technology Assessment (CCOHTA); Ottawa, Canada: 2002;
   Google Scholar
• Arseneau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 2001;120(7):1640-56
   PubMed Web of Science ®Google Scholar
• NICE. Infliximab (review) and adalimumab for the treatment of Crohn’s disease. Guidance 187 2011
   Google Scholar
• Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009;30(3):265-74
   PubMed Web of Science ®Google Scholar
• Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28(1):76-87
   PubMed Web of Science ®Google Scholar
• Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn’s disease. J Crohns Colitis 2012;6(1):77-85
   PubMed Web of Science ®Google Scholar
• Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53(10):1471-8
   PubMed Web of Science ®Google Scholar
• Rogler G. Top-down or step-up treatment in Crohn’s disease? Dig Dis 2013;31(1):83-90
   PubMed Web of Science ®Google Scholar
• Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease. Inflamm Bowel Dis 2012;18(9):1608-16
   PubMedGoogle Scholar